Stock Updates

Is this Large Market Cap Stock target price reasonable for Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)?

The company in question is, Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) currently with a stock price of 12.7 (-2.83% today). The market cap for Ariad Pharmaceuticals Inc. is 2509.31, and is in the sector Healthcare, and Biotechnology industry. The target price for Ariad Pharmaceuticals Inc. is 12.78. Currently Ariad Pharmaceuticals Inc. is trading with a P/E of *TBA, and a forward P/E of *TBA. Average volume for Ariad Pharmaceuticals Inc. is 5840.6 and so far today it is 2501613.

Performance in the last year for Ariad Pharmaceuticals Inc. has been 91.36%. For EPS growth, Ariad Pharmaceuticals Inc. has seen a growth of -40.80%, and is looking to grow in the next year to -388.90%. More long term stats show that EPS growth has been -29.50% over the last five years and could be 30.00% for the next five years. Ariad Pharmaceuticals Inc. has seen sales growth quarter over quarter at 133.20%, with EPS growth quarter over quarter at 268.60%. The 20-day simple moving average is 9.53%, with the 200-day simple moving average coming to 58.89%.

Since the IPO date for Ariad Pharmaceuticals Inc. on the 9/19/1994, Ariad Pharmaceuticals Inc. has seen performance year to date to be 109.12%. With Ariad Pharmaceuticals Inc. trading at 12.7, the dividend yield is *TBA, and the EPS is -0.33.

So could Ariad Pharmaceuticals Inc., be undervalued? Well as said before P/E is *TBA. The PEG is *TBA, P/S is 14.82 and the P/B is at *TBA. The P/cash is 9.01, with P/free cash flow at *TBA.

Ariad Pharmaceuticals Inc. ability to deal with debt shows that the current ratio is 3.1, and the quick ratio is 3. This is with long term debt/equity at *TBA, and total debt/equity at *TBA.

In terms of margins, Ariad Pharmaceuticals Inc. has a gross margin of 98.50%, an operating margin of -99.50% and a profit margin of -35.00%.Payout ratio for Ariad Pharmaceuticals Inc. is *TBA. Return on assets come to -10.50% with return on investment coming to -62.90%.

Insider ownership for Ariad Pharmaceuticals Inc., is at 0.60% and institutional ownership comes to 70.30%. Outstanding shares are at 191.99. While shares float is 186.21. The float short is currently 15.62%, and short ratio is 4.98.

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.

About the author

Peter Clarke

Leave a Comment